LCTX vs DBVT

Analysts rate Lineage Cell Therapeutics, Inc.

(LCTX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Lineage Cell Therapeutics, Inc.

(LCTX) delivered a total return of -50. 0%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: LCTX returned -51. 2% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DBV Technologies S.

A. (DBVT) is the lower-risk stock at 1. 26β versus Lineage Cell Therapeutics, Inc. 's 1. 53β — meaning LCTX is approximately 22% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Lineage Cell Therapeutics, Inc. (LCTX) carries a lower debt/equity ratio of 6% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Lineage Cell Therapeutics, Inc.

grew EPS -201. 1% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DBV Technologies S.

A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -436. 5% for Lineage Cell Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -251. 6% for LCTX. At the gross margin level — before operating expenses — LCTX leads at 99. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, DBV Technologies S.

A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Lineage Cell Therapeutics, Inc. (LCTX) carries a higher beta of 1. 53 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, LCTX: -51. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LCTX is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.